Dergiler / Glokom Katarakt / 2020 / Cilt: 15 - Sayı: 4

Cerebrotendinous Xanthomatosis as a Very Rare and Treatable Disease Frequently Overlooked: A Case Series

Sayfa
240–243
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Early diagnosis has vital importance in the prognosis of these patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Cerebrotendinous xanthomatosis (CTX) is a very rare autosomal recessive lipid storage disorder affecting bile acid biosynthesis.
📊
Temel Bulgular & Veri:Three patients with bilateral juvenile cataracts from same family were reviewed in this case series.The present case series aims to draw attention to the importance of early diagnosis for patients with CTX and to increase the awareness of physicians who have the potential to treat patients with CTX.
💡
Sonuç & Katkı:Early diagnosis has vital importance in the prognosis of these patients.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Cerebrotendinous xanthomatosis (CTX) is a very rare autosomal recessive lipid storage disorder affecting bile acid biosynthesis. It is manifested by neurologic and non-neurologic symptoms due to abnormal tissue lipid deposition. One of the early symptoms of CTX is juvenile cataract formation. Diagnosis is usually delayed but early diagnosis and replacement therapy can prevent devastating neurologic sequelae. Three patients with bilateral juvenile cataracts from same family were reviewed in this case series.The present case series aims to draw attention to the importance of early diagnosis for patients with CTX and to increase the awareness of physicians who have the potential to treat patients with CTX. Early diagnosis has vital importance in the prognosis of these patients.

🔖

Bu Makaleye Atıf Yap

KARADEMIR, Z., ONAL, H. (2020). Cerebrotendinous Xanthomatosis as a Very Rare and Treatable Disease Frequently Overlooked: A Case Series. Glokom Katarakt, Cilt: 15 - Sayı: 4, 240–243. https://ajindex.com/articles/159618

Kaynakça (14)

  1. Appadurai V, DeBar ber A, Chiang PW, et al. Apparent underdiagnosis of cerebrotendinous xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab. 2015;116:298- 304
  2. Cali JJ, Hsieh CL, Francke U, et al. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266: 7779-83
  3. Nie S, Chen G, Cao X, et al. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9:179
  4. Sandeep P, Jayakri shnan C, Sadanan S, et al. Cerebrotendinous xanthomatosis: a treatable neurodegenerative disease. J Assoc Physicians India. 2009;57:716-7
  5. Mignarri A, Gallus GN, Dotti MT, et al. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2014;37:421-9
  6. Verrips A, Hoefslo ot LH, Steenbergen GC, et al.Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain.2000;123(Pt 5):908-19
  7. Salen G, Meriwethe r TW, Nicolau G. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med.1975;14: 57-74. 8. vanHeijst AF, Verr ips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr. 1998;157: 313-6
  8. Yahalom G, Tsabari R, Molshatzki N, et al. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013;36: 78-83
  9. Barton Duell P, Sa len G, Eichler FS, et al. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. Journal of Clinical Lipidology. 2018; 12:1169-78
  10. Raymond GV, Schiff mann R. Cerebrotendinous Xanthomatosis. Neurology. 2019;92:1-2
  11. Sekijima Y, Koyama S, Yoshinaga T, et al. Nationwide survey on cerebrotendinous xanthomatosis in Japan. Journal of Human Genetics. 2018;63:2 71-80
  12. Van Heijst AFJ, Ve rips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr. 1998;157:313-6
  13. Alhariri A, Hamilt on K, Oza V, et al. Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment American Journal of Medical Genetics. 2017;173:2275-9
  14. Salen G, Steiner R D. Epidemiology, diagnosis and treatment of Cerebrotendinous xanthomatosi